Keith T. Flaherty, MD, is Professor of Medicine at Harvard Medical School, Director of the Termeer Center for Targeted Therapy, and Director of Clinical Research at the Massachusetts General Hospital Cancer Center, where he was named as the Richard Saltonstall Endowed Chair in Oncology. The goal of Dr. Flaherty's research is to understand the molecular and clinical consequences of inhibiting oncogenes and oncogenic pathways in melanoma, while establishing individual therapeutic approaches and constructing rational combinatorial therapies. A pioneer in developing targeted therapies matched to the genetic characteristics of a patient's tumor, Dr. Flaherty led early clinical trials on the development of vemurafenib and trametinib and the dabrafenib/trametinib combination.
Dr. Flaherty serves as the Editor-in-Chief of Clinical Cancer Research and is an active member of the American Association for Cancer Research. He is also the Deputy Chair for Biomarker Sciences and the Chair of the Developmental Therapeutics Committee in the Eastern Cooperative Oncology Group, a Scientific Advisory Committee member for the Melanoma Research Foundation, and a President of the Society for Melanoma Research.
Read the press release announcing Dr. Flaherty’s new position with the journal.
Clinical Cancer Research Editorial Office
American Association for Cancer Research | Publications Division
615 Chestnut Street | 17th Floor | Philadelphia, PA 19106-4404
Phone: (215) 440-9300 | Fax: (215) 440-9354 | E-mail: email@example.com